Advances in the treatment of relapsed acute promyelocytic leukemia

Acta Haematologica

Volumn 107, Issue 1, 2002, Pages 1-17

  Douer, Dan ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Acute promyelocytic leukemia; Arsenic trioxide; Molecular remission

Indexed keywords

ARSENIC TRIOXIDE; CHORIONIC GONADOTROPIN; HYBRID PROTEIN; MONOCLONAL ANTIBODY; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOTRANSPLANTATION; BIOLOGICAL MONITORING; GENETIC TRANSCRIPTION; HUMAN; MOLECULAR WEIGHT; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RELAPSE; REMISSION; REVIEW; RISK FACTOR; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ARSENICALS; BONE MARROW TRANSPLANTATION; COMBINED MODALITY THERAPY; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM, RESIDUAL; OXIDES; RECURRENCE; TRETINOIN;

EID: 0036288419     PISSN: 00015792     EISSN: None     Source Type: Journal    
DOI: 10.1159/000046623     Document Type: Review

References (116)

1. Acute promyelocytic leukemia
2. The biology of acute promyelocytic leukemia
3. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia
4. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases
5. All-trans retinoic acid for the treatment of newly diagnosed acute promyelocytic leukemia
6. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy
7. A randomized comparison of alltransretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
8. AIDA (all-trans retinoic acid + idarubicin) in newly diagnosed acute promyelocytic leukemia: A Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) pilot study
9. Molecular remission in PML/RARα-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy
10. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia
11. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the Randomized MRC Trial
12. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: An update of the New York experience
13. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
14. Long-term follow-up confirms the benefit of all-trans retinoic acid in acute promyelocytic leukemia
15. All-trans-retinoic acid in acute promyelocytic leukemia
16. All-trans retinoic acid for acute promyelocytic leukemia. Results of the New York study
17. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results
18. All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: Long-term follow-up of the New York study
19. All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia
20. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
21. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
22. Treatment of first relapse in acute promyelocytic leukaemia with all-trans retinoic acid
23. All-trans-retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
24. All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan
25. Management of acute promyelocytic leukemia relapse in the ATRA era
26. Resistance to all-trans retinoic acid (ATRA) therapy in relapsing acute promyelocytic leukemia: Study of in vitro ATRA sensitivity and cellular retinoic acid binding protein levels in leukemic cells
27. Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid
28. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation
29. Pharmacokinetics of oral all-trans retinoic acid in patients with acute promyelocytic leukemia
30. Continuous treatment with all-trans retinoic acid causes a progressive reduction in plasma drug concentrations: Implications for relapse and retinoid 'resistance' in patients with acute promyelocytic leukemia
31. Mechanisms of retinoid resistance in leukemic cells: Possible role of cytochrome P450 and P-glycoprotein
32. The level of CRABP-I expression influences the amounts and types of all-trans-retinoic acid metabolites in F9 terato-carcinoma stem cells
33. Time course of induction of metabolism of all-trans-retinoic acid and the up-regulation of cellular retinoic acid-binding protein
34. In vitro all-trans retinoic acid (ATRA) sensitivity and cellular retinoic acid binding protein (CRABP) levels in relapse leukemic cells after remission induction by ATRA in acute promyelocytic leukemia
35. Restoration of retinoid sensitivity by MDR1 ribozymes in retinoic acid-resistant myeloid leukemic cells
36. A retinoid-resistant acute promyelocytic leukemia subclone expresses a dominant negative PML-RARα mutation
37. Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARα fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy
38. Mutations in the E-domain of RARα portion of the PML/RARα chimeric gene may confer clinical resistance to all-transretinoic acid in acute promyelocytic leukemia
39. Altered ligand binding and transcriptional regulation by mutations in the PML/RARα ligand-binding domain arising in retinoic acid-resistant patients with acute promyelocytic leukemia
40. Clinical and biological characteristics of acute promyelocytic leukemia in Taiwan: A high relapse rate in patients with high initial and peak white blood cell counts during all-trans retinoic acid treatment
41. All-trans retinoic acid and chemotherapy in the treatment of acute promyelocytic leukemia
42. Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: A joint study of the PETHEMA and GIMEMA cooperative groups
43. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
44. Molecular monitoring of the myl/retinoic acid receptor-α fusion gene in acute promyelocytic leukemia by polymerase chain reaction
45. Minimal residual disease detection in acute promyelocytic leukemia by reverse-transcriptase PCR: Evaluation ofPML-RARα andRARα-PML assessment in patients who ultimately relapse
46. Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction assay for the PML/RAR-α fusion mRNA
47. Early detection of relapse by prospective reverse transcriptase-poly-merase chain reaction analysis of the PML/RARα fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial
48. Absence of reverse transcription-polymerase chain reaction detectable residual disease in patients with acute promyelocytic leukemia in long-term remission
49. Absence of detectable PML-RARα fusion transcripts in long-term remission patients after BMT for acute promy-elocytic leukemia
50. Acute promyelocytic leukemia: Clinical relevance of two major PML-RAR alpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse
51. Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor alpha clarifies diagnosis and detects minimal residual disease in acute pro-myelocytic leukemia
52. Diagnosis of acute promyelocytic leukaemia by RT-PCR: Detection of PML-RARA and RARA-PML fusion transcripts
53. The t(15;17) breakpoint in acute promyelocytic leukemia cluster within two different sites of the myl gene: Targets for the detection of minimal residual disease by the polymerase chain reaction
54. Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia
55. Prognostic significance of the RT-PCR assay of PML-RARA transcripts in acute promyelocytic leukemia
56. Molecular analysis of PML-RAR alpha fusion mRNA detected by reverse transcription-polymerase chain reaction assay in long-term disease-free acute pro-myelocytic leukaemia patients
57. PML-RAR alpha fusion transcripts by RNA PCR in acute promyelocytic leukemia in remission and its correlation with clinical outcome
58. Early detection of minimal residual disease by reverse transcriptase polymerase chain reaction predicts relapse in acute promyelocytic leukemia
59. PML-RAR alpha PCR positivity in the bone marrow of patients with APL precedes haematological relapse by 2-3 months
60. Rapid achievement of PML-RAR alpha polymerase chain reaction (PCR)- negativity by combined treatment with all-trans-retinoic acid and chemotherapy in acute promyelocytic leukemia: A pilot study
61. PML/RAR alpha transcripts monitored by polymerase chain reaction in acute promyelocytic leukemia during complete remission, relapse and after bone marrow transplantation
62. Persistence of RAR alpha-PML fusion mRNA detected by reverse transcriptase polymerase chain reaction in patients in long-term remission of acute promyelocytic leukaemia
63. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
64. Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: Prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARα fusion gene
65. The pathogenesis of acute promyelocytic leukaemia: Evaluation of the role of molecular diagnosis and monitoring in the management of the disease
66. Therapy of molecular relapse in acute promyelocytic leukemia
67. Induction of differentiation in myeloid leukemia cell lines and acute promyelocytic leukemia cells by liposomal all-trans-retinoic acid
68. Liposome encapsulation circumvents the hepatic clearance mechanisms of all-trans-retinoic acid
69. Pharmacokinetics, tissue distribution, and toxicology of tretinoin incorporated in liposomes
70. Alterations in tretinoin pharmacokinetics following administration of liposomal all-trans retinoic acid
71. Clinical relevance of all-trans retinoic acid pharmacokinetics and its modulation in acute promyelocytic leukemia
72. Treatment of newly diagnosed and relapsed acute promyelocytic leukemia with intravenous liposomal all-transretinoic acid
73. Relapsed acute promyelocytic leukemia previously treated with all-trans retinoic acid: Clinical experience with a new synthetic retinoid, Am-80
74. Good prognosis of patients with acute promyelocytic leukemia who achieved second complete remission (CR) with a new retinoid, Am80, after relapse from CR induced by all-trans-retinoic acid
75. Role of the histone deacetylase complex in acute promyelocytic leukaemia
76. In vivo treatment of human acute pro-myelocytic leukemia with a histone deacetylase inhibitor FR901228
77. Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase
78. Arsenicals and inhibitors of histone deacetylase as anticancer therapy
79. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195
80. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia
81. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: Results of MRC AML 10 trial
82. Acute promyelocytic leukemia: Biology and treatment
83. European survey of bone marrow transplantation in acute promyelocytic leukemia (M3)
84. Stem cell transplantation (SCT) for acute promyelocytic leukemia (APL) in the ATRA era: A survey of the European Blood and Marrow Transplantation Group (EBMT)
85. Prolonged molecular remission after PML/RARα-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: Is relevant pretransplant minimal residual disease in the graft?
86. Ai-Lin 1 treated 32 cases of acute promyelocytic leukemia
87. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
88. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute pro-myelocytic leukemia patients
89. 3) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients
90. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
91. Clinical experience of arsenic trioxide in relapsed acute promyelocytic leukemia
92. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
93. Arsenic trioxide (ATO) in relapsed acute promyelocytic leukemia (APL): The combined results and follow-up from the US pilot and multicenter trials
94. Arsenic trioxide (ATO): Analysis of QT prolongation on electrocardiogram (ECG)
95. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide
96. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide
97. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute pro-myelocytic leukaemia: Clinicopathological and molecular features of a pilot study
98. Arsenic trioxide as an inducer of apoptosis and loss of PML/RARα protein in acute promyelocytic leukemia cells
99. 3)
100. 3 exerts dose-dependent dual effects on APL cells
101. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
102. 4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RARα/PML proteins
103. Arsenic-induced PML targeting onto nuclear bodies: Implications for the treatment of acute promyelocytic leukemia
104. PIC-1/SUMO-1-modified PML-retinoic acid receptor α mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia
105. Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARα independent manner
106. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway
107. Arsenic trioxide induces apoptosis of myeloid leukemia cells by activation of caspases
108. Arsenic trioxide sensitivity is associated with low level of glutathione in cancer cells
109. 3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice
110. 3 sensitive relapsed acute promyelocytic leukemia
111. 3-resistant APL cells
112. Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system
113. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells
114. Arsenic trioxide and ascorbic acid: Synergy with potential implications for the treatment of acute myeloid leukaemia?
115. Multiple mechanisms are involved in differentiation induced by arsenic trioxide in acute promyelocytic leukemia
116. Efficacy of all-transretinoic acid for molecular relapse of acute promyelocytic leukemia during remission